Combined brachytherapy techniques should be 'benchmark' for cervical cancer treatment

April 24, 2015

Barcelona, Spain: The first large international study to investigate the late side-effects of a combination of two forms of brachytherapy to treat cervical cancer has shown that the technique successfully delivers higher radiation doses to the tumour without an increase in treatment-related problems afterwards.

Brachytherapy is a type of internal radiotherapy that involves putting a radioactive source close to, or in the tumour. It is often performed after a CT or MRI scan has pinpointed the exact position of the cancer, so that the radiation treatment can be targeted precisely; this is called image-guided brachytherapy (IGBT). During intracavitary (IC) brachytherapy, the radioactive applicator is placed in the uterus and the vagina, while interstitial (IS) brachytherapy involves inserting needles directly into the tumour to deliver the radiation.

In a presentation to the 3rd ESTRO Forum in Barcelona, Spain, on Saturday, Dr Lars Fokdal (MD, PhD), a consultant at the Aarhus University Hospital, Denmark, will say: "Image-guided brachytherapy has transformed treatment for cervical cancer considerably, and dose adaptation and a combination of intracavitary and interstitial brachytherapy enable us to deliver radiation that is targeted at the tumour while avoiding other organs. However, although some centres are using IC/IS brachytherapy, there are concerns that the technique might increase the likelihood of adverse side-effects occurring three months or more after the end of radiation treatment."

Dr Fokdal and colleagues in Austria, France, UK, Slovenia, The Netherlands and Ireland, enrolled 731 women with cervical cancer that had started to spread into nearby tissues (locally advanced) into the "retroEMBRACE" study - a study that collected retrospective data on the use of IGBT to treat cervical cancer in nearly 800 women in 12 different countries. The researchers analysed data from a group of 300 patients from institutions that systematically used combined IC and IS brachytherapy on more than 20% of women, and a group of 310 patients from institutions where the most common treatment used was IC brachytherapy alone.

"We found that combined IC/IS brachytherapy enabled us to deliver higher doses to the tumour without delivering more radiation to the bladder and the bowel. This meant that there was no increased risk in severe adverse side-effects three or more months later, but there is a better chance of a cure," he will tell the conference.

"These results show that combined IC/IS brachytherapy is a good treatment and should serve as a benchmark for future brachytherapy in cervical cancer."

Problems (morbidity) caused by radiotherapy for cervical cancer can include bladder and bowel dysfunction; in rare cases they can include the narrowing, loss of flexibility or drying of the vagina or bowel (known as stenosis) or holes forming in the wall of the vagina, bowel or bladder (fistulas). These are graded from 0 for no problems to 5 for death related to radiation treatment.

After a median follow-up of 40 months, ranging from three to 163 months, the researchers found there was no significant difference in late bladder, gastro-intestinal or vaginal grade 2-5 morbidities between the two groups of patients.

Among the patients in the group more likely to receive IC/IS brachytherapy, 66% (versus 52% in the other group) received high-dose rate brachytherapy, and 47% versus 4% received the combined IC/IS treatment. In addition, 97% (versus 66%) of patients in the IC/IS group benefited from their radiation doses being planned with the aid of MRI scans. Compared to the group least likely to receive IC/IS brachytherapy, the radiation dose in the IC/IS group of patients reached more of the targeted tumour area, with at least 90% of the tumours receiving a dose that was 9Gy higher than in the non-IC-IS patients. However, these higher, targeted doses in the IC/IS group of patients did not result in higher doses of radiation to the bowel, and radiation doses to the bladder was an average of 4Gy lower.

Professor Philip Poortmans, President of ESTRO, commented: "Dr Fokdal and colleagues show again that intensive close collaboration between high-level departments from several countries can help to extend our knowledge of how to further improve the outcome of our patients. This specific study of the EMBRACE network shows how the best results may be obtained by properly using the newest technical developments in the field of brachytherapy. Now, the next step is to teach these optimised techniques to all our other colleagues who treat locally advanced cervical cancer but do not yet use interstitial techniques as an addition to intracavitary ones."
-end-


European Society for Radiotherapy and Oncology (ESTRO)

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.